Back to News
Market Impact: 0.3
Zealand Pharma: Boehringer's Survodutide Delivers Up To 13.1% Weight Loss In Phase 3
Source: Nasdaq
Healthcare & Biotech
Zealand Pharma announced new Phase 3 data for survodutide, its investigational once-weekly glucagon/GLP-1 dual agonist for obesity and type 2 diabetes. The article does not disclose efficacy, safety, or other quantitative trial results, limiting assessment of the data's commercial significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ZEAL0.45
More News
- Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
- European stocks close at three-month lows as surging bond yields hammer banks
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today